Long-term clinical outcomes in cirrhotic chronic hepatitis B patients treated with tenofovir disoproxil fumarate for up to 5 years

Buti M., Fung S., Gane E., Afdhal N. H., Flisiak R., GÜREL S., ...More

HEPATOLOGY INTERNATIONAL, vol.9, no.2, pp.243-250, 2015 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 9 Issue: 2
  • Publication Date: 2015
  • Doi Number: 10.1007/s12072-015-9614-4
  • Journal Name: HEPATOLOGY INTERNATIONAL
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.243-250
  • Keywords: Antiviral agent, Chronic hepatitis B, Cirrhosis, Hepatitis B e antigen, Hepatitis B surface antigen, Tenofovir disoproxil, HEPATOCELLULAR-CARCINOMA, ADEFOVIR DIPIVOXIL, FOLLOW-UP, LAMIVUDINE, REGRESSION, THERAPY, DISEASE, LEVEL, RISK
  • Bursa Uludag University Affiliated: Yes

Abstract

Phase 3 clinical studies have shown that long-term treatment with tenofovir disoproxil fumarate (TDF) can suppress hepatitis B viral load and promote significant fibrosis regression and cirrhosis reversal in a majority of treated chronic hepatitis B (CHB) patients. This retrospective analysis investigated the impact of baseline cirrhosis status on virologic, serologic, and histologic outcomes in patients treated with TDF.